UNSPSC 51171935: Dexlansoprazole

This classification denotes a proton pump inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UYE4T5I70X. European Medicines Agency schedules Dexlansoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31929. Dexlansoprazole generally arises in the molecular formula C16H14F3N3O2S.

UNSPSC 51171935 Dexlansoprazole is a Commodity code that encompasses a specific pharmaceutical product, but the recent state and local procurement activity tagged under this code does not reflect direct purchasing of dexlansoprazole itself. Instead, the opportunities show state and local bodies procuring broader pharmaceutical services, generic multi-source drugs, and drug testing programs where dexlansoprazole may be one of hundreds of covered products rather than a named line item. Collin County Community Supervision and Corrections Department is soliciting offender specimen collection and drug testing services (RFP 2026-327, due July 23, 2026) with an estimated contract value of $600,000 and an anticipated award date of August 10, 2026; the scope includes immunoassay screening and confirmation testing across approximately 25,031 tests annually, though no specific pharmaceutical products are named. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products (RFP S1070000015802, due March 26, 2026) with evaluation weighted primarily on price competitiveness (75 percent) and compliance with cGMP and DSCSA standards; this cooperative vehicle serves state and local government facilities across participating jurisdictions including Oregon. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013, closed April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional PBM and GPO arrangements, representing early-stage market intelligence gathering rather than a committed procurement.

Recent activity under this code originates from Texas (Collin County and Texas HHS) and the multistate cooperative based in Minnesota serving multiple jurisdictions. The issuing bodies span county government (corrections department), state health and human services agencies, and cooperative purchasing organizations serving both state and local customers. Collin County's opportunity represents a narrowly defined, location-specific service contract; MMCAP's RFP reflects the broader cooperative purchasing model where pharmaceutical manufacturers supply products through authorized wholesalers under multi-year agreements, with contract awards anticipated by May 15, 2026 for July 1, 2026 implementation. The mismatch between the code's nominal scope (a single drug product) and the actual procurement activity (drug testing services, generic multi-source pharmaceutical supply agreements, and direct-to-manufacturer program exploration) suggests that dexlansoprazole itself does not drive isolated procurement at the state and local level; rather, the code appears tagged incidentally within larger pharmaceutical procurement portfolios or testing programs.